Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Aetna to move HIV drugs to lower cost-sharing tiers

    Aetna Inc. (NYSE:AET) said its CoventryOne unit will move most HIV drugs in its Florida formulary from the specialty tier to generic or non-preferred brand tiers, effective June 1. Last May, the National Health Law …

    Published on 3/30/2015
  • COMPANY NEWS: FDA panel to discuss Vertex CF combo

    FDA's Pulmonary-Allergy Drugs Advisory Committee will meet on May 12 to discuss an NDA from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) for a combination of lumacaftor (VX-809) and Kalydeco ivacaftor to treat cystic …

    Published on 3/30/2015
  • COMPANY NEWS: Fujifilm acquiring Cellular Dynamics

    Fujifilm Holdings Corp. (Tokyo:4901) is buying iPSC supplier Cellular Dynamics International Inc. (NASDAQ:ICEL) for $16.50 per share, or $307 million in cash. The price is a 108% premium to CDI's close of $7.94 on …

    Published on 3/30/2015
  • COMPANY NEWS: Horizon buying Hyperion for $1.1B

    Horizon Pharma plc (NASDAQ:HZNP) will acquire rare disease company Hyperion Therapeutics Inc. (NASDAQ:HPTX) for $46 per share, or $1.1 billion in cash. The price represents an 8% premium to Hyperion's Friday close of $…

    Published on 3/30/2015
  • COMPANY NEWS: Management tracks

    Obesity play Orexigen Therapeutics Inc. (NASDAQ:OREX) hired Tom Cannell as chief commercial officer. He will replace Mark Booth, who is departing. Cannell most recently was head of the global human health operating …

    Published on 3/30/2015
  • COMPANY NEWS: Merck Serono licenses Intrexon's CAR T tech

    The Merck Serono division of Merck KGaA (Xetra:MRK) licensed technology from Intrexon Corp. (NYSE:XON) to develop chimeric antigen receptor (CAR) T cell therapies against two undisclosed cancer targets.Merck Serono will…

    Published on 3/30/2015
  • COMPANY NEWS: Novartis, Aduro partner in STING deal

    Novartis AG (NYSE:NVS; SIX:NOVN) and Aduro Biotech Inc. (Berkeley, Calif.) partnered to develop cancer therapies using Aduro's cyclic dinucleotide (CDN) platform to generate receptor agonists of STING (transmembrane …

    Published on 3/30/2015
  • COMPANY NEWS: OptumRx acquires Catamaran, consolidating PBMs

    OptumRx Inc., the pharmacy benefit manager unit of UnitedHealth Group Inc. (NYSE:UNH), will acquire Catamaran Corp. (NASDAQ:CTRX; TSX:CCT) for $61.50 per share, or $12.8 billion in cash. The combined company expects to …

    Published on 3/30/2015
  • COMPANY NEWS: CHMP backs Eisai's Lenvima

    EMA's CHMP recommended marketing authorization for Lenvima lenvatinib from Eisai Co. Ltd. (Tokyo:4523) to treat adults with progressive, radioiodine-refractory, locally advanced or metastatic differentiated thyroid …

    Published on 3/27/2015
  • COMPANY NEWS: FDA denies Amgen's biosimilar Citizen's Petition

    FDA denied a Citizen's Petition from Amgen Inc. (NASDAQ:AMGN) asking the agency to require that biosimilar applications include a certification that the applicant will comply with the patent resolution protocol outlined…

    Published on 3/27/2015
  • COMPANY NEWS: Management tracks

    Bionor Pharma ASA (OSE:BIONOR) announced a trio of hires. Soren Keller is joining as SVP, COO and interim CFO. Keller was director and general counsel to the management at Zealand Pharma A/S (CSE:ZEAL). Kamilla Rolsted …

    Published on 3/27/2015
  • COMPANY NEWS: Celgene, MorphoSys end MOR202 deal

    MorphoSys AG (Xetra:MOR; Pink:MPSYF) plummeted EUR 14.05 (20%) to EUR 54.71 after it regained rights from Celgene Corp. (NASDAQ:CELG) to MOR202, a human mAb against CD38 in Phase I/II testing to treat multiple myeloma (…

    Published on 3/26/2015
  • COMPANY NEWS: EC approves Orexigen's Mysimba

    Orexigen Therapeutics Inc. (NASDAQ:OREX) said the European Commission approved an MAA for Mysimba naltrexone/bupropion as an adjunct to reduced-calorie diet and increased physical activity to manage weight in adults who…

    Published on 3/26/2015
  • COMPANY NEWS: Genomics England partners with industry on 100,000 Genomes Project

    Genomics England Ltd. (London, U.K.) said 10 pharma and biotech companies will form the Genomics Expert Network for Enterprises (GENE) Consortium. The group will collaborate with and analyze data from the U.K.'s 100,000…

    Published on 3/26/2015
  • COMPANY NEWS: Management tracks

    Jeffrey Yordon retired as chairman and CEO of specialty pharma Sagent Pharmaceuticals Inc. (NASDAQ:SGNT). Also, President James Hussey is departing. Yordon will remain a director. Board member Frank Kung will become …

    Published on 3/26/2015
  • COMPANY NEWS: Sovaldi among several Japan approvals

    Japan's Ministry of Health, Labor and Welfare (MHLW) approved Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) and a basket of other drugs on Thursday.In Japan, Gilead said Sovaldi is indicated in combination …

    Published on 3/26/2015
  • COMPANY NEWS: Amgen appeals biosimilar case to CAFC

    Amgen Inc. (NASDAQ:AMGN) filed an appeal to the U.S. Court of Appeals for the Federal Circuit (CAFC) Wednesday, after a district court last week denied the company's motions intended to prevent the Sandoz unit of …

    Published on 3/25/2015
  • COMPANY NEWS: Emergent's anthrax treatment gets FDA nod

    FDA approved a BLA for Anthrasil anthrax immune globulin IV (AIGIV) from Emergent BioSolutions Inc. (NYSE:EBS) to treat inhaled anthrax. The drug, developed using plasma collected from healthy donors vaccinated with the…

    Published on 3/25/2015
  • COMPANY NEWS: FDA approves Eylea for diabetic retinopathy

    FDA approved Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat diabetic retinopathy in patients with diabetic macular edema (DME). The human fusion protein that binds all forms of VEGF-A and …

    Published on 3/25/2015
  • COMPANY NEWS: Management tracks

    Pain company Egalet Corp. (NASDAQ:EGLT) hired Wendy Niebler as SVP of clinical development and medical affairs, a newly created position. Niebler was VP and head of global medical affairs at PTC Therapeutics Inc. (…

    Published on 3/25/2015
  • COMPANY NEWS: BMS scoops up Novo autoimmune program

    Bristol-Myers Squibb Co. (NYSE:BMY) acquired an exclusive global license to a research program from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) that modulates the innate immune system to treat autoimmune diseases. Specifics of…

    Published on 3/24/2015
  • COMPANY NEWS: Calico, QB3 start research collaboration

    Calico LLC (South San Francisco, Calif.) and the California Institute for Quantitative Biosciences (QB3) started a four-year partnership to investigate the biology of aging and age-related diseases.Calico will fund …

    Published on 3/24/2015
  • COMPANY NEWS: Management tracks

    The Innovative Medicines Initiative (IMI) named Marc de Garidel as chair of its governing board. Garidel succeeds Roch Doliveux, who retired last year. Garidel is chairman and CEO of Ipsen Group (Euronext:IPN; Pink:…

    Published on 3/24/2015
  • COMPANY NEWS: Biogen drops Idec from name

    Biogen (NASDAQ:BIIB) changed its name from Biogen Idec Inc. The company had been called Biogen Idec since Biogen Inc. merged with Idec Pharmaceuticals Corp. in 2003.Biogen's shares fell $12.25 to $463.73 on Monday.

    Published on 3/23/2015
  • COMPANY NEWS: EC approves Novo's Saxenda

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said the European Commission approved an MAA for Saxenda liraglutide for weight management as an adjunct to diet and exercise in obese adults or in overweight adults with at least …

    Published on 3/23/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993